The use of interferon beta at the time of initial diagnosis of multiple sclerosis

Journal of Clinical Neuroscience

Volumn 8, Issue 4, 2001, Pages 381-382

  P Pender, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HIGH RISK PATIENT; HUMAN; MULTIPLE SCLEROSIS; PATIENT SELECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SPASTICITY;

EID: 0034912060     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2001.0913     Document Type: Article

References (8)

1. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b
2. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
3. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
4. Autoimmune events during interferon beta-1b treatment for multiple sclerosis
5. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis
6. Clinical toxicity of the interferons
7. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families
8. Inhibition of B cell receptor-mediated apoptosis by IFN